Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials

Background: Revefenacin, a novel, lung-selective, long-acting muscarinic antagonist, has been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We present the results of replicate Phase III efficacy and safety studies of revefenacin in patients with moderate to very s...

Full description

Saved in:
Bibliographic Details
Published in:Chronic Obstr Pulm Dis
Main Authors: Ferguson, Gary T., Feldman, Gregory, Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Pendyala, Srikanth, Crater, Glenn
Format: Artigo
Language:Inglês
Published: COPD Foundation Inc 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6596436/
https://ncbi.nlm.nih.gov/pubmed/30974049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.6.2.2018.0152
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items